Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review
- 14 December 2024
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 39 (3) , 460-467
Abstract
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes. A review of relevant studies from PubMed, EMBASE, and Open Access databases was conducted, focusing on studies investigating the role of MTX in PVR. Study characteristics, patient demographics, dosages, administration frequency, and patient outcomes were extracted. Vitrectomy with various additional procedures such as laser photocoagulation, scleral buckling, gas tamponade and membranectomy were performed during primary and repeated surgery. Among the 180 eyes studied, those receiving MTX through intravitreal injection or intraoperative infusion showed promising outcomes, with retinal reattachment rates ranging from 74 to 92%. Eyes that received MTX infusion intraoperatively had an average retinal reattachment rate of 85%. Improvement in Best Corrected Visual Acuity was also observed in all eyes receiving MTX, with low rates of adverse events reported. Re-operation rates for repeated retinal detachment is significantly lower at 18% for eyes that received MTX treatment compared to those who did not receive MTX at initial surgery. Despite positive findings, further research is needed due to limitations such as small number of studies, low quality of evidence, and heterogeneity in treatment regimens. While MTX shows potential as an adjunctive treatment for PVR in RRD, more robust studies are necessary to confirm its efficacy.Keywords
This publication has 30 references indexed in Scilit:
- Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129–1141)Ophthalmology, 2023
- Inhibition of proliferative vitreoretinopathy by a newly developed methotrexate loaded drug carrier in vitroBiomedicine & Pharmacotherapy, 2022
- Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and reviewInternational Ophthalmology, 2020
- Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathyScientific Reports, 2019
- Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblastMolecular and Cellular Biochemistry, 2015
- Intraocular Methotrexate in Ocular Diseases Other Than Primary Central Nervous System LymphomaAmerican Journal of Ophthalmology, 2006
- Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvementHistorical imageOphthalmology, 2002
- Cytokines in proliferative vitreoretinopathyEye, 1991
- Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 1991